Page last updated: 2024-08-24

atorvastatin and mycophenolic acid

atorvastatin has been researched along with mycophenolic acid in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (30.00)29.6817
2010's7 (70.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Andricopulo, AD; Moda, TL; Montanari, CA1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Chang, G; DeNofrio, D; Goldberg, L; Kao, A; Kolansky, DM; Loh, E; Pickering, F; Sasseen, B; See, VY; Wilensky, RL1
Brunet, M; Cofán, F; Cofán, M; Guillén, D; Millán, O; Ros, E1
Aref, A; Ehsanpour, A; Ghorbani, A; Shahbazian, H1
Gabriel, CL; Kastelein, JJ; Major, AS; Mendez-Fernandez, YV; Stroes, ES; Tak, PP; van Leuven, SI; Wade, NS; Wilhelm, AJ1
Burger, D; Maliepaard, M; Neef, C; Teerenstra, S; Yu, Y1
Bernabei, E; Caramiello, MS; Centi, A; Di Franco, D; Di Vasta, G; Dominijanni, S; Guido, G; Londrino, F; Palumbo, R; Tatangelo, P1

Reviews

1 review(s) available for atorvastatin and mycophenolic acid

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

3 trial(s) available for atorvastatin and mycophenolic acid

ArticleYear
Effect of atorvastatin on postcardiac transplant increase in low-density lipoprotein cholesterol reduces development of intimal hyperplasia and progression of endothelial dysfunction.
    The American journal of cardiology, 2003, Jul-01, Volume: 92, Issue:1

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Disease Progression; Endothelium, Vascular; Female; Heart Transplantation; Heptanoic Acids; Humans; Hyperplasia; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Postoperative Period; Pyrroles; Tunica Intima

2003
Biomarker assessment of the immunomodulator effect of atorvastatin in stable renal transplant recipients and hypercholesterolemic patients.
    Molecular diagnosis & therapy, 2010, Dec-01, Volume: 14, Issue:6

    Topics: Adenosine Triphosphate; Adult; Aged; Atorvastatin; Biomarkers; Cell Proliferation; Culture Media, Conditioned; Cytokines; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Hypercholesterolemia; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Pyrroles; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Tacrolimus; Transplantation

2010
Alteration of panel-reactive antibodies following treatment with either atorvastatin or low-dose mycophenolate mofetil in sensitized hemodialysis patients.
    Iranian journal of kidney diseases, 2011, Volume: 5, Issue:5

    Topics: Adult; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Failure, Chronic; Male; Mycophenolic Acid; Pyrroles; Renal Dialysis

2011

Other Studies

6 other study(ies) available for atorvastatin and mycophenolic acid

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice.
    Annals of the rheumatic diseases, 2012, Volume: 71, Issue:3

    Topics: Animals; Atherosclerosis; Atorvastatin; CD4-Positive T-Lymphocytes; Cholesterol; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Cellular; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Mice; Mice, Inbred C57BL; Mycophenolic Acid; Pyrroles

2012
Investigation into the interchangeability of generic formulations using immunosuppressants and a broad selection of medicines.
    European journal of clinical pharmacology, 2015, Volume: 71, Issue:8

    Topics: Anilides; Area Under Curve; Atorvastatin; Benzodiazepines; Chemistry, Pharmaceutical; Cyclosporine; Drugs, Generic; Humans; Immunosuppressive Agents; Mycophenolic Acid; Nitriles; Olanzapine; Perindopril; Piperidines; Tacrolimus; Therapeutic Equivalency; Tosyl Compounds; Tryptamines; Venlafaxine Hydrochloride

2015
[Steroid-resistant focal segmental glomerulosclerosis treated with cascade plasmafiltration and rituximab].
    Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2018, Volume: 35, Issue:3

    Topics: Adrenal Cortex Hormones; Adult; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Combined Modality Therapy; Diuretics; Drug Resistance; Drug Therapy, Combination; Glomerulosclerosis, Focal Segmental; Humans; Immunosuppressive Agents; Male; Mycophenolic Acid; Plasmapheresis; Platelet Aggregation Inhibitors; Rituximab; Salvage Therapy

2018